BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32413280)

  • 1. Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.
    Yang L; Wang L; Huo Y; Chen X; Yin S; Hu Y; Zhang X; Zheng R; Geng H; Han H; Ma X; Liu M; Li H; Yu W; Liu M; Wang J; Li D
    Mol Ther; 2020 Jul; 28(7):1673-1683. PubMed ID: 32413280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
    Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
    J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenine base editing in an adult mouse model of tyrosinaemia.
    Song CQ; Jiang T; Richter M; Rhym LH; Koblan LW; Zafra MP; Schatoff EM; Doman JL; Cao Y; Dow LE; Zhu LJ; Anderson DG; Liu DR; Yin H; Xue W
    Nat Biomed Eng; 2020 Jan; 4(1):125-130. PubMed ID: 31740768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I.
    Li N; Gou S; Wang J; Zhang Q; Huang X; Xie J; Li L; Jin Q; Ouyang Z; Chen F; Ge W; Shi H; Liang Y; Zhuang Z; Zhao X; Lian M; Ye Y; Quan L; Wu H; Lai L; Wang K
    Mol Ther; 2021 Mar; 29(3):1001-1015. PubMed ID: 33221434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
    Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
    J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
    Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
    Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.
    Yin H; Xue W; Chen S; Bogorad RL; Benedetti E; Grompe M; Koteliansky V; Sharp PA; Jacks T; Anderson DG
    Nat Biotechnol; 2014 Jun; 32(6):551-3. PubMed ID: 24681508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo.
    Paulk NK; Wursthorn K; Wang Z; Finegold MJ; Kay MA; Grompe M
    Hepatology; 2010 Apr; 51(4):1200-8. PubMed ID: 20162619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA.
    Villiger L; Rothgangl T; Witzigmann D; Oka R; Lin PJC; Qi W; Janjuha S; Berk C; Ringnalda F; Beattie MB; Stoffel M; Thöny B; Hall J; Rehrauer H; van Boxtel R; Tam YK; Schwank G
    Nat Biomed Eng; 2021 Feb; 5(2):179-189. PubMed ID: 33495639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of a Mouse Model of ALS by In Vivo Base Editing.
    Lim CKW; Gapinske M; Brooks AK; Woods WS; Powell JE; Zeballos C MA; Winter J; Perez-Pinera P; Gaj T
    Mol Ther; 2020 Apr; 28(4):1177-1189. PubMed ID: 31991108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient Gene Silencing by Adenine Base Editor-Mediated Start Codon Mutation.
    Wang X; Liu Z; Li G; Dang L; Huang S; He L; Ma Y; Li C; Liu M; Yang G; Huang X; Zhou F; Ma X
    Mol Ther; 2020 Feb; 28(2):431-440. PubMed ID: 31843453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction.
    Koblan LW; Doman JL; Wilson C; Levy JM; Tay T; Newby GA; Maianti JP; Raguram A; Liu DR
    Nat Biotechnol; 2018 Oct; 36(9):843-846. PubMed ID: 29813047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer.
    Hickey RD; Lillegard JB; Fisher JE; McKenzie TJ; Hofherr SE; Finegold MJ; Nyberg SL; Grompe M
    Hepatology; 2011 Oct; 54(4):1351-9. PubMed ID: 21674562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
    Morrow G; Angileri F; Tanguay RM
    Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1.
    Hickey RD; Nicolas CT; Allen K; Mao S; Elgilani F; Glorioso J; Amiot B; VanLith C; Guthman R; Du Z; Chen H; Harding CO; Kaiser RA; Nyberg SL; Lillegard JB
    Cell Transplant; 2019 Jan; 28(1):79-88. PubMed ID: 30477316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
    Zhang L; Shao Y; Li L; Tian F; Cen J; Chen X; Hu D; Zhou Y; Xie W; Zheng Y; Ji Y; Liu M; Li D; Hui L
    Sci Rep; 2016 Aug; 6():31460. PubMed ID: 27510266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
    Wu G; Liu N; Rittelmeyer I; Sharma AD; Sgodda M; Zaehres H; Bleidissel M; Greber B; Gentile L; Han DW; Rudolph C; Steinemann D; Schambach A; Ott M; Schöler HR; Cantz T
    PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
    Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
    Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.
    Yin H; Song CQ; Dorkin JR; Zhu LJ; Li Y; Wu Q; Park A; Yang J; Suresh S; Bizhanova A; Gupta A; Bolukbasi MF; Walsh S; Bogorad RL; Gao G; Weng Z; Dong Y; Koteliansky V; Wolfe SA; Langer R; Xue W; Anderson DG
    Nat Biotechnol; 2016 Mar; 34(3):328-33. PubMed ID: 26829318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.